Scotland's national economic development agency operating as a non-departmental public body to foster business innovation and scale.
The financing round was co-led by World Fund and CPT Capital to help scale sustainable protein production in Europe.
"Our strides in launching the new factory in the Netherlands and expanding collaborations across the UK and Europe have been significant. This fresh funding will drive accelerated growth."
The funding will increase clinical capacity and support the delivery of Phase I trials for novel medicines.
"BDD is an excellent example of an ambitious and innovative Scottish life science company with global reach. Its patented timed-release technology, alongside world-class clinical trial services offering, created a compelling proposition for the pharma industry. Building on a successful 18 months after the challenges of the pandemic, the company is well poised to pursue its growth strategy. We’re excited by what the future holds for BDD and looking forward to supporting Carol and the team."
The investment round was led by Archangels to help the life science firm advance its cell analysis platform.
"We are uniquely positioned in harnessing the power of consumer electronics technology to meet the emerging, complex needs of the bioprocess industry. On the back of a very successful year for Cytomos, this new funding will now allow us to scale up our engagement with industry partners. We truly believe that, through our CDS technology, we offer a powerful platform which will help the scientific community bring novel therapies to market faster and radically reduce costs by making better informed, game-changing decisions a lot earlier."
Northstar Ventures and Par Equity co-led the investment round to support international expansion and US regulatory clearance.
"I’d like to thank Manus’ existing investors for supporting the Company’s commercialisation programme of our unique NeuroMotor PenTM , building on previous support we received in 2021. This year is set to be an exciting one, with partnerships already secured, and we truly believe our non-invasive and CE-marked product can have a huge impact on patients and tackle the unmet need for a quick, inexpensive device that can detect neurological conditions, particularly given the ageing global population."
The Glasgow-based ophthalmic technology company has raised £4.5m from Compiler VC, Deepbridge, and Scottish Enterprise.
"The commitment of our investor base shows they believe strongly in our story — that eyecare will be at the vanguard of remote healthcare, and IbisVision has the technology to make this a reality. Our mission is simple – to make eyecare readily available for anyone on the planet and that distance and time will never be an impediment to getting to an eye appointment."
